Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Gosogliptin in Type 2 Diabetes on Metformin
NCT00473525Phase 2Completed
- Sponsor
- Pfizer
- Start
- Jul 2007
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of gosogliptin in type 2 diabetes mellitus (T2DM) (5 arms), sponsored by Pfizer. Primary endpoints: HbA1C levels at 12 weeks and Evaluation of Dose Response in HbA1c at 12 weeks. Started Jul 2007; status: completed.
02
Drugs
gosogliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00473525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00473525.